arrow
D

Deborah Watson-Jones

University of London
H指数:39
被引数:5,852

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls

疟疾寄生虫血症对单剂量和双剂量HPV疫苗接种后抗体反应的影响:来自坦桑尼亚女孩DoRIS减量免疫原性试验的结果

Vaccine
IF3.5
2026-06-010
OAAI
A qualitative exploration of perceived risks, motivations, and risk management strategies among brothel-based female sex workers in Ibadan, Nigeria

对尼日利亚伊巴丹地区妓院从业女性性工作者感知风险、动机及风险管理策略的定性探索

2025-12-240
OAAI
Knowledge and acceptability of male HPV vaccination among young people and community stakeholders in northwest Tanzania: social sciences in the Add-Vacc trial

坦桑尼亚西北部年轻人和社区利益相关者对男性HPV疫苗接种的认知与接受度:Add-Vacc试验中的社会科学研究

Vaccine
IF3.5
2025-11-270
OAAI
Assessment of Relative Contributions of Lifestyle, Behavioral and Biological Risk Factors for Cervical Human Papillomavirus Infections in Female Sex Workers

评估生活方式、行为及生物风险因素对女性性工作者宫颈人乳头瘤病毒感染的相对贡献

2025-03-280
OA
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo

刚果民主共和国成人和儿童Ad26.ZEBOV,mva-bn-filo埃博拉疫苗方案延长剂量间隔的免疫原性

2024-07-230
OAAI
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo

刚果民主共和国暴发期间孕妇和非孕妇两剂预防性埃博拉病毒疾病疫苗的分娩和安全性

2024-07-231
OAAI
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study
2024-02-172
OAAI
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults
2023-11-159
OAAI
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active- controlled trial in Guinea and Sierra Leone
2023-11-015
OAAI
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen

先前暴露于疟疾感染和临床疟疾发作对两剂Ad26.ZEBOV,mva-bn-filo埃博拉疫苗方案的免疫反应的影响

2023-08-020
OAAI
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory
2023-05-011
OAAI
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial
2023-03-0112
OAAI
Immunogenicity and Safety of One-Dose Human Papillomavirus Vaccine Compared With Two or Three Doses in Tanzanian Girls (DoRIS): An Open-Label, Randomised, Non-inferiority Trial

在坦桑尼亚女孩 (DoRIS) 中,一剂人乳头瘤病毒疫苗与两剂或三剂疫苗的免疫原性和安全性比较: 一项开放标签,随机,非劣效性试验

2023-03-010
OA
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone
2022-03-013
OAAI
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
2022-01-0157
OAAI
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
2022-01-0155
OAAI